<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03674502</url>
  </required_header>
  <id_info>
    <org_study_id>ADU-CL-17</org_study_id>
    <nct_id>NCT03674502</nct_id>
  </id_info>
  <brief_title>Safety of ADU-1604 in Adults With Metastatic Melanoma</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aduro Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aduro Biotech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human, open-label, multicenter, dose-escalation study designed to
      evaluate the safety, PK, and PD of ADU-1604 and explore initial clinical activity in adults
      with metastatic melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADU-CL-17 is a first-in-human, open-label, multicenter, dose-escalation study designed to
      evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ADU-1604, an
      anti-CTLA-4 monoclonal antibody, and explore initial clinical activity in adults with
      metastatic melanoma. The primary objective of the study is to determine the Recommended Phase
      2 Dose (RP2D) of ADU-1604 administered by IV infusion once every 3 weeks for 4 doses.

      The study will be conducted in two parts: Dose Escalation followed by Dose Confirmation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to business realignment
  </why_stopped>
  <start_date type="Actual">November 8, 2018</start_date>
  <completion_date type="Actual">August 9, 2019</completion_date>
  <primary_completion_date type="Actual">August 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the recommended P2 dose (RP2D) of ADU-1604 administered as an IV infusion</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>ADU-1604</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADU-1604 administered as an IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADU-1604</intervention_name>
    <description>anti-CTLA-4 monoclonal antibody</description>
    <arm_group_label>ADU-1604</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥18 years

          2. Histologically-confirmed metastatic or unresectable melanoma

          3. Progression of disease following at least one prior therapy, and is not a candidate
             for, or is intolerant to, established therapy known to provide clinical benefit (i.e.
             available treatment options have been exhausted). Subjects must have BRAF mutation
             status confirmed; if a subject is BRAF V600E/K positive, they must have received a
             BRAF- targeted regimen prior to entering the study, unless the patient was deemed
             ineligible for such treatment

          4. Measurable disease according to RECIST (v1.1) [NOT required during Dose Escalation]

          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

        Exclusion Criteria:

          1. Prior diagnosis of uveal or mucosal melanoma

          2. Prior treatment with CTLA-4-directed therapy in the metastatic setting. Use of CTLA-
             4-directed treatment in the adjuvant or neoadjuvant setting is acceptable provided the
             last dose was &gt;6 months before the first dose of ADU-1604 and there was no
             discontinuation of treatment due to a treatment-related toxicity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave- Roussy Institute</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

